BioNxt Solutions Inc.
BNXTF
$0.25
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -198.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -198.78% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -198.78% | |||
| SG&A Expenses | 75.46% | 34.03% | |||
| Depreciation & Amortization | -75.00% | -20.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 60.95% | 34.08% | |||
| Operating Income | -59.91% | -36.14% | |||
| Income Before Tax | -81.55% | -44.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -98.25% | -32.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -98.25% | -32.26% | |||
| EBIT | -59.91% | -36.14% | |||
| EBITDA | -60.25% | -36.40% | |||
| EPS Basic | -93.65% | -27.27% | |||
| Normalized Basic EPS | -34.12% | -41.67% | |||
| EPS Diluted | -93.65% | -27.27% | |||
| Normalized Diluted EPS | -34.12% | -41.67% | |||
| Average Basic Shares Outstanding | 2.78% | 3.59% | |||
| Average Diluted Shares Outstanding | 2.78% | 3.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||